




April 13, 1999 9 5 8 '99 APR 20 P2:09



Linda S. Kahl, Ph.D.
Office of Special Nutritionals
Center for Food Safety and Applied Nutrition
Food and Drug Administration
200 "C" St. S.W. (HFS-450)
Washington, D.C. 20204

Dear Dr. Kahl:

NaturaLife Corporation wishes to notify the Food and Drug Administration that it has, within the past 30 days, commenced marketing a dietary supplement which bears a statement under Section(r)(6) of the Federal Food, Drug and Cosmetic Act.

The dietary supplement for which the statement is made is Boswellia. The dietary ingredient that is the subject of the statement is Boswellia. The statement reads as follows:

"Supports joint health & mobility. Boswellia has been the focus of research for its health benefits associated with the support of joint health and mobility."

This statement is accompanied by the required disclaimer which is prominently displayed in bold-faced type.

The information contained in this notice is complete and accurate and the above statement is based on data which renders these statements substantiated, truthful and non-misleading.

Sincerely,

NATURALIFE CORPORATION

Gordon M. Walker
Regulatory Counsel

lre

Gordon\Letter\Kahl-NL-Boswellia

97S-0162

LET3509